Results of the international SELECT-GCA study suggest that upadacitinib may be an effective new oral treatment for giant cell arteritis.
Search results for: cardiovascular disease
The Secret Lives of the Rheumatologist
Clark Kent, Hannah Montana, Dexter Morgan, David Bowie and your friendly neighborhood rheumatologist: What do all of these people have in common? Chances are, they live secret lives we rarely get to peer into. Unlike Superman, Miley Stewart, Dexter Morgan and Ziggy Stardust, rheumatologists are very much real, flesh-and-blood characters. Rheumatologists also have secret lives…
Positive Week 12 Results for Rosnilimab in Patients with RA
Early study results demonstrate that rosnilimab may be safe and effective for patients with rheumatoid arthritis, reducing the signs and symptoms of RA by week 12 and achieving important primary and secondary study end points.
FDA Approves Upadacitinib for GCA
Supported by data in patients with new-onset and relapsing giant cell arteritis (GCA), the FDA approved upadacitinib for the treatment of adults with GCA.
Key Research in Axial Spondyloarthritis Encapsulated
Our understanding of (axSpA) has really changed, especially with regard to male-female differences. In this report, we identify important research on axSpA presented at ACR Convergence 2024, summarize the abstracts and comment on why each is important, addressing the relevance for clinicians and the potential impact on future research.
It’s Not Just Joint Pain
Experts offered perspectives on how symptoms of rheumatic disease, such as fatigue, affect the physical, cognitive and emotional health of patients and offered solutions.
Can Primary Care Physicians Help Rheumatology’s Workforce Shortages?
In an effort to ameliorate serious rheumatology provider shortages, the ACR Workforce Solutions Committee has developed a new resource for primary care providers who treat patients with rheumatic conditions.
15,000 Patient-Years: Safety Data for Upadacitinib Treatment Across Multiple Rheumatic Conditions
Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
Lupus: Closer to a Cause?
Two studies outline the roles of air pollution and T cell imbalance in the pathogenesis of systemic lupus erythematosus.
FDA Approves 2 Upadacitinib Formulations for Children with pJIA & PsA
Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.
- « Previous Page
- 1
- …
- 37
- 38
- 39
- 40
- 41
- …
- 66
- Next Page »